Skip to main content
← All exclusions

Guardant Health, Inc.

GH

Health Care

2

exclusion reasons

1 theme

Animal Welfare (2)
GH Health Care Current as of March 2026

Guardant Health, Inc. is screened out under 2 exclusion reasons spanning 1 issue category.

This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.

Animal Exploitation
Since Jan 3, 2022

Guardant Health develops and commercializes blood-based cancer diagnostic tests, including its Guardant360 and Guardant Reveal products. The company's core business involves the development and validation of liquid biopsy assays, a process that historically and currently relies on animal testing for research and regulatory compliance. While the company's 2025 corporate responsibility report outlines general ethical principles, it does not disclose a formal animal testing policy, alternative methods commitment, or third-party cruelty-free certification for its diagnostic development pipeline. The absence of such commitments, combined with the standard industry practice for novel in-vitro diagnostic (IVD) regulatory submissions, indicates ongoing reliance on animal models.

Animal Testing & Research
Since Jul 28, 2021

Guardant Health, Inc. develops and commercializes blood-based cancer diagnostic tests, including its FDA-approved Shield test for colorectal cancer screening. The company's regulatory filings indicate that its product development process involves non-clinical laboratory tests and animal studies as required for FDA premarket submissions. For example, its Investigational Device Exemption (IDE) applications, a precursor to FDA approval, must be supported by data from animal and laboratory testing to demonstrate safety. The company is listed by Cruelty Free Investors as conducting animal testing. As a developer of in vitro diagnostic devices in the highly regulated medical field, Guardant Health's product pipeline is subject to FDA requirements that typically mandate animal testing to establish safety and efficacy prior to human clinical trials.

Research Sources 1 organization
Cruelty Free Investors
External

Wondering what we do invest in?

The Naughty List

A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.

RSS feed No spam · Unsubscribe anytime

Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.

This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.

Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.